Biosimilars/Biobetters Pipeline Directory        
The most comprehensive and cost-effective follow-on biopharmaceuticals (biosimilars, biobetters and biogenerics) pipeline resource 

  • Find competing products and companies; product/API licensing sources; collaborators and partners; customers for your products, technologies and services
  • 1,775 product records include 1,050+ biosimilars, 560+ biobetters, 150+ reference products; plus 790+ involved company records [as of 7/9/2019]
  • Web database (Products and Companies) subscription plans for individuals and company-wide access
  • Developed by the author of BIOPHARMA:  Biopharmaceutical Products in the U.S. and European Markets, still the only information resource/reference specializing in biopharmaceuticals, now archived as "The Reference Products' Reference."  The BIOPHARMA online database includes compiled and estimated U.S. and European patent and regulatory exclusivity expiration dates (marketability dates) for all reference products.  Ask about bundled discounts to the Pipeline and BIOPHARMA databases.
  • Order/Inquiry (direct with the author/publisher); also available from resellers
  • Satisfaction guaranteed!  Full refund within 1 month, e.g., if you do not learn information that critically affects your company.

Description/Flyer:  Further information
Users Guide
Enter password for database access: followed by CR/enter

Biosimilars/Biobetters Pipeline Directory - Top Level Data (as of 7/9/2019)

  • product entries = 1,775
  • R&D pipeline products (biosimilars + biobetters) = 1,621
  • biosimilars = 1,055
  • biobetters = 566
  • ref. products = 158
  • companies = 791 [in separate relational database]
The Biosimilars/Biobetters Pipeline Directory covers only recombinant (great majority) and other cell culture/fermentation-manufactured protein products.  Vaccines, blood/plasma-derived, cellular and gene therapy products not included. 
[Note, biosimilar and biobetter U.S. and EU launchable dates (patent, data and market exclusivity expirations) are reported for the reference products in BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets, "The Reference Products' Reference]." 

Near-term economic impact includes biosimilars sooner or later in the U.S. and European markets for the ~50, nearly all recombinant, mostly monoclonal antibody, products with over $1 billion/year sales, and 20+ others with sales over $500 million/year. 

The table above shows country or regions and the numbers of biosimilars and biobetters associated with companies based (with headquarters) in these countries/regions.  The U.S. is by far the leader in both biosimilars and biobetters.  As a region/continent, Asia is by far the leader in biosimilars (although most are more biogenerics vs. biosimilars in more highly-regulated markets).  China is now pulling ahead of India in terms of biosimilars/biogenerics, while also having many more biobetters in the pipeline vs. India.

The table above shows the distribution of products by their highest phase of development attained in any country (with phase in the U.S. and Europe also searchable). Product entries are indexed and the online database allows searching of products, including prospective genuine biosimilars, being developed initially or primarily for highly-regulated country markets (>400 products) vs. biogenerics (>700; usually called 'biosimilars' by their developers).
      Note, most of the 'marketed biosimilars' in developing markets are biogenerics -- finished products that are rather similar (e.g., same generic API-based names used) to established major market reference products, but are not manufactured to highly-regulated country (e.g., U.S., EU) GMP standards and/or are or will not be rigorously (by highly-regulated country standards) tested analytically and clinically in comparison with their reference product. Biogenerics are sold in lesser- and non-regulated international commerce often based simply on meeting pharmacopeial standards for the reference product; including often sold through tenders/RFPs (a gov't essentially orders from a lowest-bidder company acting as a CMO). With work and investment, biogenerics may become approvable as biosimilars in highly-regulated countries.

Some Popular Targeted Reference Products
[No. of biosimilars by reference product]
Epoetin alfa 98
Neupogen 69
Interferons (alfa) 141
Insulin and analogs 82
Rituxan 60
Herceptin 69
Humira 50
Avastin 57
Somatropins 43
Enbrel 41
Neulasta 38
Remicade 21
Lantus 17
Cancer indications 590
mAbs, mAb fragments      416
The table above shows the number of biosimilars (not including biobetters) targeted to some popular reference products and product classes.

Companies With the Largest Biosimilars Pipelines (10 or more; 1/2019)

Harvest Moon Pharmaceuticals USA, Inc. 28
Bioviz Technologies Pvt. Ltd. 25
Pfizer 21
BioXpress Therapeutics S.A. 20
Reliance Life Sciences Pvt. Ltd. 19
Mylan Labs. 18
Sandoz AG/Novartis AG 17
Chemo Group (Grupo Insud ) 15
Dong-A Pharmaceutical. 15
Creative Biomart Inc. 15
UGA Biopharma GmbH 14
LG Life Sciences Ltd. 14
Inbiopro Solutions Pvt Ltd. 14
Dr. Reddy's Labs. 14
Bio Sidus S.A. 14
Intas Biopharmaceuticals Ltd. 13
Hospira/Pfizer 13
Biocon Ltd. 13
Zhejiang HISUN Pharmaceuticals Co. Ltd./3S Bio. 12
SciGen Ltd. (Bioton) 12
GC Corp./Green Cross Corp. 12
AXXO GmbH 12
Amega Biotech 12
Zydus Cadilla Healthcare Ltd. 11
Viropro Inc. 11
BioGenomics Ltd. 11
Siam Bioscience 10
Lupin Ltd. 10
Cassara Biotech 10
Biocad Biotechnological Co. 10
Amgen 10
Companies with the largest biosimilars portfolios (not including biobetters) are shown above. Note, multiple companies are often involved with a product (developers, partners, licensees, CMO manufacturers, etc.). Information Resources A variety of unique follow-on biopharmaceutical-related information resources are available or planned:

Some related articles by the database author:

Need a Consultant With Biosimilars Expertise? - Contact Biotechnology Information Institute for world-class expertise concerning biopharmaceutical information, products, technologies, and related market, technology and policy assessments.  

    Contact information: